Literature DB >> 7307317

Mannosidosis: two brothers with different degrees of disease severity.

M L Mitchell, R P Erickson, D Schmid, V Hieber, A K Poznanski, S P Hicks.   

Abstract

Two siblings with different degrees of mental retardation, skeletal dysplasia, coarse facies, delayed speech, motor incoordination, recurrent respiratory infections, and immunological abnormalities, were found to have deficient alpha-mannosidase activity. Cultured skin fibroblasts in one sib were markedly deficient in alpha-mannosidase while all other lysosomal enzymes tested were within the normal range. The more severely affected sib came to autopsy and was found to have "washed-out" appearing cortical neurons and marked histiocytosis effacing lymph node architecture and partially replacing the bone marrow. The post-mortem brain and liver samples demonstrated a deficiency in alpha-mannosidase relative to the elevations of other lysosomal enzymes. Although the patterns of abnormalities in the two cases closely match those of descriptions of "type II" and "type I" mannosidosis respectively, the variation should be due to genetic modifiers or environmental effects since the brothers must have shared similar alpha-mannosidase mutations. Immunologic abnormalities present in the more severely affected sib suggest that the differential survival seen in mannosidosis types I and II may be due to differences in their immune systems.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307317     DOI: 10.1111/j.1399-0004.1981.tb01829.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  10 in total

1.  The effects of early and late bone marrow transplantation in siblings with alpha-mannosidosis. Is early haematopoietic cell transplantation the preferred treatment option?

Authors:  A A Broomfield; A Chakrapani; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2010-02-18       Impact factor: 4.982

2.  Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis.

Authors:  L Borgwardt; A M Thuesen; K J Olsen; J Fogh; C I Dali; A M Lund
Journal:  J Inherit Metab Dis       Date:  2015-05-28       Impact factor: 4.982

3.  Skeletal muscle pathology of mannosidosis in two siblings with spastic paraplegia.

Authors:  H Kawai; H Nishino; Y Nishida; K Yoneda; Y Yoshida; T Inui; K Masuda; S Saito
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

4.  Alpha- and beta-mannosidoses.

Authors:  A Cooper; C E Hatton; M Thornley; I B Sardharwalla
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

5.  Distribution of central nervous system lesions in beta-mannosidosis.

Authors:  K L Lovell; M Z Jones
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

6.  Axonal and myelin lesions in beta-mannosidosis: ultrastructural characteristics.

Authors:  K L Lovell; M Z Jones
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

7.  Spectrum of mutations in alpha-mannosidosis.

Authors:  T Berg; H M Riise; G M Hansen; D Malm; L Tranebjaerg; O K Tollersrud; O Nilssen
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

8.  Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation.

Authors:  Line Borgwardt; Hilde Monica Frostad Riise Stensland; Klaus Juul Olsen; Flemming Wibrand; Helle Bagterp Klenow; Michael Beck; Yasmina Amraoui; Laila Arash; Jens Fogh; Øivind Nilssen; Christine I Dali; Allan Meldgaard Lund
Journal:  Orphanet J Rare Dis       Date:  2015-06-06       Impact factor: 4.123

Review 9.  Mortality in patients with alpha-mannosidosis: a review of patients' data and the literature.

Authors:  Julia B Hennermann; Eva M Raebel; Francesca Donà; Marie-Line Jacquemont; Graziella Cefalo; Andrea Ballabeni; Dag Malm
Journal:  Orphanet J Rare Dis       Date:  2022-07-23       Impact factor: 4.303

Review 10.  Alpha-mannosidosis.

Authors:  Dag Malm; Øivind Nilssen
Journal:  Orphanet J Rare Dis       Date:  2008-07-23       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.